GENENTECH, INC for GENENTECH INC
What was lobbied
6 issue areas, each in the filer's own words, with who lobbied on it and where.
Pharmacy PHA
PHA: proposed cuts to Part B reimbursement. 340b reimbursement policy;
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | Director |
| DARIN GARDNER | Sr. Director |
| KATHERINE RAAB | Director |
Taxation/Internal Revenue Code TAX
TAX Monitoring proposals on US tax treatment of foreign-owned US Corporations; general tax issues and tax extenders (R&D tax credit) and tax treatment of foreign-owned US corporations.Research and Development Tax credit, alternative sales pricing; R&D Tax Credit (H.R. 942) FDA Appropriations, PDUFA Reauthorization; Issues related to comprehensive tax reform, tax treatment of foreign-owned U.S. corporations, and tax extenders, including R & D tax credit. S.3521, Family and Business Tax Cut Certainty Act of 2012 (tax extenders). Corporate tax reform issues (no specific legislation) Implementation of healthcare reform law. FDA drug approval and appeal oversight process. Issues related to patient and physician choice in medical treatments. PDUFA reauthorization. FY13 appropriations bills, including issues related to FDA funding and drug approval/review oversight process. Legislation related to altering sequestration targets. Issues related to comprehensive tax reform, tax treatment of foreign-owned U.S. corporations, and tax extenders, including R & D tax credit. S.3521, Family and Business Tax Cut Certainty Act of 2012 (tax extenders). Corporate tax reform issues (no specific legislation)
| Lobbyist | Covered position, as disclosed |
|---|---|
| DARIN GARDNER | Director |
| EVAN MORRIS | Vice President |
| KATHERINE RAAB | Director |
Copyright/Patent/Trademark CPT
Cyber security, Implementation of S.23: America Invents Act, Implementation of HR 1249: Leahy-Smith America Invents Act., Transpacific partnership
| Lobbyist | Covered position, as disclosed |
|---|---|
| DARIN GARDNER | Sr. Director |
Health Issues HCR
Implementation of healthcare reform law. FDA drug approval and appeal oversight process. Issues related to patient and physician choice in medical treatments. PDUFA reauthorization; FY12 Labor HHA Appropriations legislation; issues related to FDA user fee reauthorization; H.R. 3630, A bill to exten the payroll tax holiday and for other purposes; Implementation of H.R. 1: Medicare Prescription Drug and Modernization Act of 2003; Issues relating to PDUFA stimulus. Legislation on public health preparedness and response related to pandemic influenza. Avastin-use in breast cancer treatment: general patient reform isse: implementation of the Affordable Care Act of 2010; Affordable Care Act Health reform; Implementation of Health Reform; Medicare/Medicaid Reimbursement: Legislation for CMS
| Lobbyist | Covered position, as disclosed |
|---|---|
| DARIN GARDNER | Sr. Director |
| EVAN MORRIS | Vice President |
Medicare/Medicaid MMM
MMM: implementation of H.R. 1; Medicare Prescription Drug and Modernization Act of 2003; Issues related to the PPS rule involving stroke guidelines. Proposals to reduce Medicare payment for Part B biologics. Concerns regarding Medicare payment policies for Biologics; Monitor implementation of Medicare pharmaceutical coverage and reimbursement and 340B provisions of the Affordable Care Act; Proposed cuts to Part B reimbursement
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | Director |
| KATHERINE RAAB | Director |
Budget/Appropriations BUD
FY13 Labor, HHS and Education Appropriation related to preparedness for pandemic influenza, HIV/AIDS programs, hepatitis screeinng, care and treatmen, and access to breast cancer treatment.;Following issues related to the budget and appropriations process FY 13 appropriations for FDA as awell as the potential outcomes for negotiations on altering sequestration targets via legislation.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | Director |
| DARIN GARDNER | Director |
| ELI KOGAN | Assoc. Director |
| EVAN MORRIS | Vice President |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.